Roivant Sciences (NASDAQ:ROIV) Hits New 1-Year High on Analyst Upgrade

Roivant Sciences Ltd. (NASDAQ:ROIV) hit a new 52-week high during mid-day trading on Wednesday after HC Wainwright raised their price target on the stock from $33.00 to $34.00. HC Wainwright currently has a buy rating on the stock. Roivant Sciences traded as high as $29.72 and last traded at $28.93, with a volume of 1839027 shares trading hands. The stock had previously closed at $27.85.

Several other research analysts have also issued reports on the company. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Guggenheim increased their price target on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday. Citigroup upped their target price on Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Finally, TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Saturday, February 7th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus target price of $28.81.

Insider Transactions at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $21.96, for a total transaction of $43,389,841.68. Following the completion of the sale, the insider owned 36,350,621 shares of the company’s stock, valued at $798,259,637.16. This trade represents a 5.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $23.04, for a total transaction of $21,134,177.28. Following the completion of the sale, the director owned 17,130,445 shares of the company’s stock, valued at $394,685,452.80. This represents a 5.08% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 13,318,014 shares of company stock valued at $315,727,023. 10.80% of the stock is owned by insiders.

Trending Headlines about Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant (via subsidiary Genevant) and Arbutus announced a $2.25 billion global settlement with Moderna that includes a $950M upfront payment and up to $1.3B contingent on a favorable appeal — a major cash and litigation-risk removal for Roivant’s LNP business. Read More.
• Positive Sentiment: The board approved an expanded $1 billion share repurchase program (inclusive of a prior $500M authorization), which supports buyback-driven EPS/reduced share float dynamics and likely contributed to the rally. Read More.
• Positive Sentiment: Priovant (a Roivant affiliate) received FDA acceptance and Priority Review for brepocitinib in dermatomyositis with a PDUFA date in Q3 2026 — approval would create a first-in-class targeted therapy and potential commercial upside. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $34 and maintained a Buy rating, providing analyst support and signaling ~15% upside from current levels. Read More.
• Neutral Sentiment: The $1.3B additional payment is contingent on a favorable resolution of Moderna’s Section 1498 appeal — meaningful upside but dependent on litigation outcome and timing, introducing uncertainty to the total cash Roivant ultimately receives. Read More.
• Negative Sentiment: Pfizer/BioNTech litigation remains ongoing in the U.S.; while the Moderna settlement materially de-risks one front, continued legal exposure and appeals across the sector leave some patent and revenue uncertainty. Read More.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. UBS Group AG grew its stake in Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after acquiring an additional 15,645,836 shares during the period. Morgan Stanley grew its position in Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after purchasing an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. increased its stake in Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after purchasing an additional 8,621,567 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Roivant Sciences by 11,507.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after buying an additional 6,877,348 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Roivant Sciences in the fourth quarter valued at $112,750,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Stock Up 6.0%

The stock has a market capitalization of $21.13 billion, a P/E ratio of -25.23 and a beta of 1.17. The business’s 50 day simple moving average is $24.28 and its two-hundred day simple moving average is $19.85.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.